vs
Side-by-side financial comparison of BLACKLINE, INC. (BL) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $183.2M, roughly 1.5× BLACKLINE, INC.). BLACKLINE, INC. runs the higher net margin — 2.7% vs -45.7%, a 48.4% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 8.1%). BLACKLINE, INC. produced more free cash flow last quarter ($26.1M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 7.9%).
BlackLine Systems, Inc., is an American enterprise software company that develops cloud-based services designed to automate and manage the entire financial close process as well as consolidation, invoice-to-cash, and intercompany accounting. The Los Angeles–based company has 17 offices worldwide.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
BL vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.2M | $281.3M |
| Net Profit | $4.9M | $-128.5M |
| Gross Margin | 75.2% | 64.6% |
| Operating Margin | 3.7% | -43.0% |
| Net Margin | 2.7% | -45.7% |
| Revenue YoY | 8.1% | 39.4% |
| Net Profit YoY | -91.3% | -15.8% |
| EPS (diluted) | $0.07 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.2M | $281.3M | ||
| Q3 25 | $178.3M | $265.2M | ||
| Q2 25 | $172.0M | $232.1M | ||
| Q1 25 | $166.9M | $203.5M | ||
| Q4 24 | $169.5M | $201.8M | ||
| Q3 24 | $165.9M | $191.5M | ||
| Q2 24 | $160.5M | $177.2M | ||
| Q1 24 | $157.5M | $168.5M |
| Q4 25 | $4.9M | $-128.5M | ||
| Q3 25 | $5.3M | $-92.7M | ||
| Q2 25 | $8.3M | $-99.9M | ||
| Q1 25 | $6.1M | $-95.2M | ||
| Q4 24 | $56.4M | $-111.0M | ||
| Q3 24 | $17.2M | $-107.8M | ||
| Q2 24 | $76.7M | $-102.6M | ||
| Q1 24 | $10.8M | $-115.0M |
| Q4 25 | 75.2% | 64.6% | ||
| Q3 25 | 75.1% | 64.7% | ||
| Q2 25 | 75.2% | 65.0% | ||
| Q1 25 | 75.5% | 63.3% | ||
| Q4 24 | 75.6% | 61.6% | ||
| Q3 24 | 75.2% | 61.1% | ||
| Q2 24 | 74.9% | 59.1% | ||
| Q1 24 | 75.2% | 61.2% |
| Q4 25 | 3.7% | -43.0% | ||
| Q3 25 | 4.3% | -37.3% | ||
| Q2 25 | 4.4% | -45.9% | ||
| Q1 25 | 2.1% | -54.6% | ||
| Q4 24 | 3.7% | -62.4% | ||
| Q3 24 | 5.0% | -61.3% | ||
| Q2 24 | 1.4% | -56.8% | ||
| Q1 24 | 1.1% | -59.2% |
| Q4 25 | 2.7% | -45.7% | ||
| Q3 25 | 3.0% | -35.0% | ||
| Q2 25 | 4.8% | -43.0% | ||
| Q1 25 | 3.6% | -46.8% | ||
| Q4 24 | 33.3% | -55.0% | ||
| Q3 24 | 10.4% | -56.3% | ||
| Q2 24 | 47.8% | -57.9% | ||
| Q1 24 | 6.9% | -68.2% |
| Q4 25 | $0.07 | $-1.01 | ||
| Q3 25 | $0.09 | $-0.74 | ||
| Q2 25 | $0.13 | $-0.80 | ||
| Q1 25 | $0.10 | $-0.77 | ||
| Q4 24 | $0.79 | $-0.90 | ||
| Q3 24 | $0.27 | $-0.88 | ||
| Q2 24 | $0.22 | $-0.84 | ||
| Q1 24 | $0.17 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $390.0M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $332.3M | $-99.3M |
| Total Assets | $1.8B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $390.0M | $378.2M | ||
| Q3 25 | $419.9M | $580.0M | ||
| Q2 25 | $459.1M | $629.1M | ||
| Q1 25 | $479.5M | $698.6M | ||
| Q4 24 | $885.9M | $525.5M | ||
| Q3 24 | $725.3M | $585.0M | ||
| Q2 24 | $616.6M | $933.7M | ||
| Q1 24 | $331.4M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $332.3M | $-99.3M | ||
| Q3 25 | $328.3M | $-354.5M | ||
| Q2 25 | $414.0M | $-305.5M | ||
| Q1 25 | $417.9M | $-250.8M | ||
| Q4 24 | $446.7M | $-139.6M | ||
| Q3 24 | $367.9M | $-60.1M | ||
| Q2 24 | $325.8M | $-1.6M | ||
| Q1 24 | $279.8M | $68.3M |
| Q4 25 | $1.8B | $2.0B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.8B | $1.3B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.8B | $1.5B | ||
| Q3 24 | $1.7B | $1.5B | ||
| Q2 24 | $1.9B | $1.6B | ||
| Q1 24 | $2.1B | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.7M | $-26.4M |
| Free Cash FlowOCF − Capex | $26.1M | $-54.2M |
| FCF MarginFCF / Revenue | 14.2% | -19.3% |
| Capex IntensityCapex / Revenue | 0.3% | 9.9% |
| Cash ConversionOCF / Net Profit | 5.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | $161.5M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.7M | $-26.4M | ||
| Q3 25 | $63.8M | $-35.4M | ||
| Q2 25 | $32.3M | $-60.3M | ||
| Q1 25 | $46.7M | $-62.7M | ||
| Q4 24 | $43.8M | $-64.5M | ||
| Q3 24 | $55.9M | $-51.1M | ||
| Q2 24 | $40.7M | $-94.0M | ||
| Q1 24 | $50.4M | $-30.3M |
| Q4 25 | $26.1M | $-54.2M | ||
| Q3 25 | $63.3M | $-45.8M | ||
| Q2 25 | $31.4M | $-65.9M | ||
| Q1 25 | $40.8M | $-67.1M | ||
| Q4 24 | $43.0M | $-83.4M | ||
| Q3 24 | $55.5M | $-55.3M | ||
| Q2 24 | $40.0M | $-99.1M | ||
| Q1 24 | $50.1M | $-37.2M |
| Q4 25 | 14.2% | -19.3% | ||
| Q3 25 | 35.5% | -17.3% | ||
| Q2 25 | 18.2% | -28.4% | ||
| Q1 25 | 24.4% | -33.0% | ||
| Q4 24 | 25.4% | -41.3% | ||
| Q3 24 | 33.5% | -28.9% | ||
| Q2 24 | 24.9% | -55.9% | ||
| Q1 24 | 31.8% | -22.1% |
| Q4 25 | 0.3% | 9.9% | ||
| Q3 25 | 0.3% | 3.9% | ||
| Q2 25 | 0.6% | 2.4% | ||
| Q1 25 | 3.6% | 2.2% | ||
| Q4 24 | 0.4% | 9.4% | ||
| Q3 24 | 0.2% | 2.2% | ||
| Q2 24 | 0.4% | 2.9% | ||
| Q1 24 | 0.2% | 4.1% |
| Q4 25 | 5.46× | — | ||
| Q3 25 | 12.07× | — | ||
| Q2 25 | 3.90× | — | ||
| Q1 25 | 7.72× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | 3.24× | — | ||
| Q2 24 | 0.53× | — | ||
| Q1 24 | 4.66× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BL
| Subscription And Circulation | $173.2M | 95% |
| Technology Service | $10.0M | 5% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
